Navigating Liver Cancer Care – Liver Cancers News

Navigating Liver Cancer Care – Liver Cancers News

Liver Cancer News Banner


Liver Cancer Care: Management of Hepatic Encephalopathy, Ascites, & Portal Hypertension

Please join us on April 18 for a liver cancer care webinar open to patients, caregivers, and health care professionals. Experts will discuss topics relevant to the care and treatment of liver cancer and its symptoms so that patients and providers alike can make informed care decisions.

Liver Cancer Care (1)

 

Stanford study suggests new screening guidelines for diabetes and liver cancer

Individuals with diabetes are two to three times more likely to develop liver cancer than those without it. Recently, researchers have discovered that individuals with type 2 diabetes have elevated levels of advanced glycation end products (AGEs), a form of protein or lipid that form after exposure to sugar. High levels of AGEs cause the liver to become more elastic, which can cause liver cells to behave invasively. Liver elasticity, just like liver stiffness, can be screened for by a non-invasive magnetic resonance elastography, a preventive and non-invasive screening that could be made available to high-risk individuals with diabetes.


 

One Liver to Love conversation cards released

Global Liver Institute has partnered with One Liver To Love to bring patients and their families educational resources and support services to help navigate the challenges of liver cancer. These conversation starters have been crafted to create easy entry points for considerate and insightful conversations about the day-to-day challenges faced by individuals with liver cancer and their loved ones. Whether it involves tactfully seeking assistance or employing empathetic strategies to comprehend each other’s needs, these cards can be valuable tools to overcome the common discomfort around open and effective communication about liver cancer care.

Screenshot 2024 03 05 At 2.14.35 PM

 

Finding the right target to treat biliary tract cancers 

Biliary tract cancer (BTC) cholangiocarcinoma, a rare form of primary liver cancer. Currently, BTC has a high mortality rate with a five-year survival rate ranging from 2% to 23% per the NCI’s SEER database. To increase BTC survival rates, researchers are exploring multiple targeted therapies that target fibroblast growth factor receptors 2 (FGFR2) inhibitors or the immune checkpoint molecule PD-1. These therapies have shown some increase in survival time, but researchers aim to develop a treatment that can significantly extend patients’ lives.

Bile Duct Cancer Awareness 0224 300x225.jpg

 

Canadian/French research team identifies biomarker related to treatment failure 

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer with low five-year survival rates relative to other primary cancers. Approximately 75% of patients with advanced HCC who seek treatment fail to respond to immunotherapy. Professor Maya Saleh and her team have focused on finding a biomarker for patients whose HCC is associated with fatty liver disease. Their research revealed that chronic inflammation from fatty liver disease leads to the expansion of immunosuppressive cells that express an inflammatory receptor known as TREM1, which hinders the ability of the body’s immune system to attack the tumor. This biomarker, however, could be a promising target for treatment of HCC patients with a history of fatty liver disease.


 

Sanofi guarantees employees a year’s salary after cancer diagnosis 

After a cancer diagnosis, many employees hesitate to inform their employers of their illness for fear of losing their jobs. However, Sanofi, GLI partner and a global healthcare and pharmaceutical company, has taken a commendable step by guaranteeing their employees’ salaries and benefits for at least twelve months after a cancer diagnosis. Through their Cancer & Work: Acting Together support program, Sanofi has already assisted two hundred employees and provided them with access to confidential cancer counseling. Other employers who wish to champion the health and well-being of their employees (especially those who may face cancer) should look to this program as an exemplar of comprehensive social, emotional, and financial support.


 

Liver cancer impact in Mississippi among largest in the U.S.

Rates of liver cancer have been on the rise globally for the past 30 years. However, in the United States, Mississippi stands out with a significant increase in death rates, particularly among white men, who have the second highest rates of liver cancer deaths in the country. The state has high rates of hepatitis B and hepatitis C infections, which are major risk factors for liver cancer. These infections are often transmitted through the sharing of contaminated needles during drug use and unprotected sex. To combat this issue, individuals at risk must seek screening for HBV, HCV, and liver cancer to reduce the rates of liver cancer in the state.


 

Upcoming Events:


 

For more information about the Liver Cancers Council or to learn more about joining, please visit https://globalliver.org/liver-cancers-council/ or email cancer@globalliver.org

Rare Advocacy on Capitol Hill, in the White House, & Beyond! – Pediatric & Rare Liver Diseases News

Rare Advocacy on Capitol Hill, in the White House, & Beyond! – Pediatric & Rare Liver Diseases News

New Banner 02


 

 

A Successful #RareAware Campaign 

In February, GLI raised awareness and amplified the patient voice in discussions about transitions in care for rare liver diseases. 

Here are a few highlights:

1. Through a series of listicles, experts shared their insights to help healthcare professionals support liver patients through transitions: 

2. Donna R. Cryer, JD, discussed the challenges and successes of different transitions in care with rare liver disease patients and caregivers through weekly conversations on GLI LIVE

3. Release of a new pocket card for patients to ask physicians when they are prescribed a new medication.

    Rareaware 01

     

    Advocacy in Rare Liver Diseases

    Throughout February, many organizations advocated on behalf of rare diseases. Together, we fought for acknowledgment and prioritization of rare conditions in healthcare.

    • We participated in webinars, awareness campaigns, and social media storytelling for Rare Disease Day.
    • GLI partnered with Everylife Foundation for Rare Disease Week on Capitol Hill to advocate for the Medical Nutrition Equity Act (H.R. 6892) and reform in FDA drug approvals for rare diseases.
    IMG 5662
    Screenshot 2024 02 27 At 2.31.17 PM (1)
    IMG 5693

     

    White House holds first Rare Disease Forum

    During the first Rare Disease Forum hosted at the White House this year, Shonta Chambers, GLI board member, moderated an enlightening session on technological breakthroughs in rare diseases. The discussion covered the active roles of patient advocacy groups in research, highlighting resources like the NCATS program and the IAMRARE registry. Panelists discussed innovations including AI and gene therapy advancements.

    White House Office Of Science And Technology Policy Rare Disease Forum Shonta Chambers 3

     

    Intercept’s obetacholic acid reaches new FDA milestone

    We are thrilled to celebrate with Intercept on the FDA’s acceptance of their Supplemental New Drug Application (sNDA) for obeticholic acid for PBC. This sNDA is expected to satisfy requirements to confirm clinical benefit, after obeticholic acid has been on the market. It is encouraging to see the evidence of real-world impacts for patients with PBC.

    Intercept

     

    The impact of socioeconomic factors on pediatric acute liver failure

    In a recent study led by Dr. Johanna Ascher Bartlett at Children’s Hospital Los Angeles, has revealed new insights about pediatric acute liver failure (PALF). The findings indicate that socioeconomic factors such as family support, patient age, race, employment status, and language proficiency can significantly impact clinical outcomes. With this, Dr. Bartlett and others from CHLA recommend that other health systems screen for these factors and collaborating with community health organizations to address inequities in their communities.

    CHLA Butterfly Logo® No Tagline

     

    Screening assay may improve early Wilson disease detection

    Screening procedures worldwide are crucial for the early detection and treatment of rare liver diseases. Though Wilson disease meets the criteria for universal screening, no population screening protocol exists. However, promising developments are underway. Key Proteo, in collaboration with the Washington State Department of Health Office of Newborn Screening and Seattle Children’s Research Institute, is researching an in vitro diagnostics assay for Wilson disease screening, which may mean the disease is added to newborn screening protocols.

    KeyProteo+Logo+Black+Transparent+File

     

    Navigating the Niche Nutritional Challenges of Rare Liver Diseases 

    Struggling with dietary restrictions due to a rare liver condition? You’re not alone. Dive into specialized nutrition tips for Wilson Disease, LAL-D and more! Learn more in GLI‘s latest article


     

    New explanation for the increase in viral hepatitis cases in children caused by unknown origin  

    New cases of viral hepatitis of unknown origin in children have surged globally, with approximately 1,000 cases reported from 35 countries in 2022 alone. While the cause remains unclear, ongoing research released in the Journal of Infection suggests a potential link to simultaneous infections by multiple viruses. Researchers are investigating associations with infections involving multiple helper cells, COVID-19, and other respiratory and enteric pathogens.


     

    Upcoming Events


     

    For more information about the Pediatric and Rare Liver Diseases Council or to learn more about joining, please visit our webpage or email pedsrare@globalliver.org.

    6 Ways to Ease Financial Stress for Patients with Chronic Liver Conditions

    6 Ways to Ease Financial Stress for Patients with Chronic Liver Conditions

    6 Ways to Ease Financial Stress for Patients with Chronic Liver Conditions 

    Dr. Nneka Ufere is a transplant hepatologist at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School. Her research focuses on health services and patient-centered outcomes in the areas of hepatology, transplant, and palliative care. She also tests supportive care interventions to increase the quality of life and care for cirrhosis patients and families as a clinical trialist. In 2024, Dr. Ufere received the Young Physician Scientist Award from the American Society for Clinical Investigation. 

    Dr. Ufere has published more than 70 peer-reviewed publications. Her recent publications are featured in journals like Kidney360, Hepatology Communications, and Liver Transplantation. The full list of Dr. Ufere’s publications can be viewed here

    Dr. Ufere spoke with GLI about the financial insecurities of patients with chronic liver disease. In her experience, the decision to seek medical care often boils down to affordability, at the end of the day. “The loss of household income due to medical costs may force patients to have to make tradeoffs between paying for their medications to manage their chronic liver disease or paying for their basic necessities, such as housing or food – a critical sign of financial distress. This leads to a feedback loop of worsening health and worsening financial burden, which can lead to adverse outcomes such as worsening health-related quality of life, increasing hospitalizations, and increasing caregiver burden, which are signs of financial toxicity.” 

    Read on to learn 6 ways healthcare facilities can ease the financial burdens faced by patients with chronic liver conditions. 

    1. Implement standard screening during clinic visits for financial stress

    Integrating universal screening for financial burdens during clinic visits, particularly in rural or low-income areas, can better support patients and their families. Creating a standardized scoring system can help identify reasons why patients may struggle to access healthcare services, allowing for tailored accommodations, especially for those managing chronic conditions. Dr. Ufere suggests incorporating questions such as:

    • Are you having difficulty paying for your medical care?
    • Do you have obstacles that would make it difficult to pay for medical care?
    • Have you delayed getting care in the past 12 months because you did not have transportation?

    Leveraging nonprofit organizations and local networks can also aid in conducting thorough analyses of the financial challenges patients encounter as well. Through these measures, it will be easier to identify why patients are not coming to get the care they need and also accommodate bringing them to their check-ups. 

    2. Deprescribe unnecessary medications and discuss lower-cost alternatives to reduce out-of-pocket expenses

    On average, patients with chronic liver conditions may take anywhere from three to 10 medications simultaneously, with costs varying based on insurance coverage. Healthcare professionals need to monitor medication responses and discontinue unnecessary ones promptly. This not only saves the patients from spending extra money on unnecessary medication but also prioritizes patient health. Dr. Ufere also suggests exploring the use of websites like costplusdrugs.com for affordable alternatives. Patients must be informed of all available options, considering the large financial impact medications can have. Providers should explore alternatives with their patients and should openly discuss effective options like using a generic. 

    3. Discuss the pricing of medication transparently and provide early assistance for prescription drug prices 

    Often, patients are only aware of their medication costs once they reach the pharmacy counter. To adhere to their medication regimen effectively, patients need to know the costs and have the chance to plan accordingly. Dr. Ufere’s scoping review on financial burden outlines various strategies to aid liver disease patients and their families. One effective strategy involves early referral to co-pay and drug assistance programs, facilitated by pharmacy services. This initiative assists patients in managing prescription costs upon diagnosis, while also facilitating informed decisions about their medication based on affordability.

      4. Collaborate with financial navigators early 

      Due to the limited accessibility of information, liver disease patients often struggle to find resources to manage the financial burdens associated with their condition. Patients with liver disease have expressed a desire for early financial navigation support. Financial navigators help patients comprehend the costs related to their illness and identify strategies and resources like employment assistance or disease-specific funds to mitigate financial strain. Dr. Ufere recommends that healthcare providers and the health system collaborate with financial navigators to address patient needs. 

      piggy bank

      5. Provide transportation and parking vouchers for clinic visits

      Adults with chronic liver conditions with transportation insecurities have a significantly higher risk of mortality, approximately double the risk compared to those without. The main factors contributing to these challenges are often the costs associated with public transportation, gas, and parking. Hospital systems and networks should consider offering community-appropriate services such as: 

      • Hospital shuttles that make home visits 
      • Free or reimbursed parking for clinic visits 
      • Coupons for rideshare programs 

      These resources can alleviate the burden of arranging transportation for clinic visits. Dr. Ufere stresses that “many specialized healthcare facilities for chronic liver conditions are limited and located in areas where transportation costs are high or too far away; therefore, providing patients with these resources will ease the strain for patients who may not always have the means to travel independently.”  

      6. Provide caregiver support and training to allow them to give better care 

      Financial burdens put a strain on caregivers as well. Increased out-of-pocket costs and increased hospitalizations associated with advanced chronic liver disease can elevate caregiver burden. Caregivers can also experience wage loss if they have to take time off work to travel to specialist appointments. Dr. Ufere says that providing caregivers with support and training on how to care for their loved ones can show them how to efficiently manage medical care while minimizing unnecessary expenses. Initiatives like a support group for caregivers can help them identify strategies to better support their loved ones.


       

      For more information about the Pediatric and Rare Liver Diseases Council or to learn more about joining, please visit our webpage or email pedsrare@globalliver.org.

      Navigating the Niche Nutritional Challenges of Rare Liver Diseases

      Navigating the Niche Nutritional Challenges of Rare Liver Diseases

      Navigating the Niche Nutritional Challenges of Rare Liver Diseases 

      The lifestyle changes that come with a rare liver disease or any chronic condition can be daunting and frustrating. With a diet change, your meals, grocery bills, and even restaurant menus start to look different, not to mention the lists and diet recommendations from doctors that can be long and overwhelming. Many rare liver diseases require specialized nutrition to manage or improve health. 

      Lysosomal lipid lipase deficiency (LAL-D) is a rare genetic disorder that affects the breakdown of lipids. It leads to the accumulation of lipids in various tissues, causing a range of health issues including hepatomegaly, which is an enlarged liver.

      1. Restrict the intake of saturated fats and cholesterol, while making sure to include healthy fats such as monounsaturated and polyunsaturated fats found in foods such as avocados, nuts, and fish. 
      2. Maintain a well-balanced diet with adequate intake of vitamins and minerals to manage complications. 
      3. Manage caloric intake and monitor lipid levels to avoid excessive weight gain. 

      Glycogen storage disorders are a group of rare genetic disorders characterized by the body’s inability to break down glycogen, a form of glucose (sugar) typically found in the liver/muscles, which can cause liver damage. Symptoms usually appear within the first year of a child’s life. 

      1. Avoid fasting and eat frequent small meals and snacks to maintain glucose levels. 
      2. Choose carbohydrates wisely; complex carbohydrates such as grains and legumes release glucose slowly, while simple sugars can cause unsustained energy levels. 
      3. Eat uncooked cornstarch or similar supplements to help maintain stable blood sugar levels over long periods. 

      Hereditary hemochromatosis is a rare genetic disorder identified by excessive absorption of iron by the intestines, which can lead to an accumulation of iron in various organs, including the liver. 

      1. Limit iron-rich foods such as red meat, organ meats, and shellfish as well as iron supplements to avoid excess iron in the diet. 
      2. Choose non-heme iron, found in plant foods such as beans, lentils, and tofu. 
      3. Avoid vitamin C supplements or foods high in vitamin C since it enhances the absorption of nonheme iron.
      4. Limit alcohol consumption, as it can increase iron absorption. 

      Wilson’s disease is a rare genetic disorder leading to copper accumulation in organs, including the liver. 

      1. Eat a low copper diet, limiting foods such as shellfish, nuts, chocolate, and mushrooms. 
      2. Avoid food cooked with copper utensils. 
      3. Take zinc under the guidance of a healthcare professional, which can inhibit the absorption of copper. 

      Alagille syndrome is a rare genetic disorder that primarily impacts the liver and is caused by mutations in genes that play essential roles in fetal development. 

      1. Consume a nutrient-dense, high-calorie diet to support weight gain and growth. Protein intake is also important for growth and muscle development. 
      2. Supplements for vitamins (A, D, E, and K), calcium, and zinc may be recommended due to difficulties with absorption.
      3. Calcium and vitamin D are recommended for bone health. 
      4. Consume a low-fat diet to manage symptoms such as diarrhea and malnutrition. 

      Tyrosinemia is a rare metabolic genetic disorder that impacts the body’s ability to break down tyrosine, a type of amino acid (the building blocks of proteins). 

      1. Limit protein intake to reduce the accumulation of tyrosine in the body. 
      2. Restrict foods such as meat, fish, eggs, some grains, and dairy products. 
      3. For tyrosinemia (type I), seek a prescription for a medical formula that provides nutrients without causing further metabolic imbalance. Other vitamin and mineral supplements may also be needed. 

      These recommendations may not apply to every individual case. Not only is regular monitoring of development and nutrition levels critical, but it is also important to seek guidance from a healthcare professional to manage your condition. Time, money, and access may also affect the ability to follow these guidelines. 

      Medical Nutrition Equity Act and Looking Forward 

      Many individuals in the U.S. struggle with digestive or inherited metabolic disorders, like rare liver disease, making certain foods hard to eat. According to Patients and Providers For Medical Nutrition Equity, without proper medically necessary nutrition, the risk of toxic accumulation or inadequate nutrient absorption increases. Specifically, in chronic liver disease, vitamin replacement therapy, and specialized nutrition are critical for symptom management, particularly for children who often face even more severe health consequences. Obtaining medically necessary nutrition comes with significant costs – but without it, patients often end up with even more costly hospital stays. Insurance companies generally do not cover medically necessary nutrition, preferring to cover more expensive pharmaceuticals.

      Brooke Lark LcZ9NxhOSlo Unsplash

      GLI is pleased to support the Medical Nutrition Equity Act (H.R. 6892), which provides for the coverage of medically necessary food, vitamins, and individual amino acids for digestive and inherited metabolic disorders under Federal health programs and private health insurance, as well as ensuring State and Federal protection for existing coverage. Malabsorption due to liver or pancreatic disease is explicitly included in coverage under the bill’s provisions. The passage of the Medical Nutrition Equity Act could be life-changing for those diagnosed and managing rare liver disease. Key potential impacts could include improved access, affordability, and health outcomes across the U.S. 

      Reliable Resources, Meal Guides, and Information 

      Glycogen Storage Disease 

      Hereditary Hemochromatosis 

      Wilsons Disease 

      Alagille Syndrome  

      LAL-D 

      ​​Tyrosinemia  


       

      For more information about the Pediatric and Rare Liver Diseases Council or to learn more about joining, please visit our webpage or email pedsrare@globalliver.org.

      Six Tips to Help Your Patients through Organ Transplantation

      Six Tips to Help Your Patients through Organ Transplantation

      Six Tips to Help Your Patients through Organ Transplantation

      Dr. Alin Gragossian is a physician trained in both emergency medicine and critical care medicine at Equum Medical. Beyond her clinical roles, she serves as an associate medical director at Donor Network West, a nonprofit, organ procurement and tissue recovery organization serving Nevada and California. Notably, Dr. Gragossian brings a unique perspective to her work, having undergone a heart transplant in 2019 at the age of 30. 

      Drawing from her personal journey, she emphasizes the importance of tailoring care approaches to individual experiences including aspects such as navigating post-transplant monitoring and fostering open communication between patients and providers. Dr. Gragossian also emphasizes some lesser-known elements of the transplant process that can facilitate a smoother transition. 

      1. Address new mental stressors 

      Recovery often focuses on the physical changes resulting from transplantation, but mental health poses a challenge to a patient’s well-being, too. These patients may experience anxiety, adjustment disorders, or psychological changes due to medications. Steroids in particular can induce mood swings and cause sleep disturbances. As a patient and a physician, Dr. Gragossian says, “I was much more prepared for the physical things that were going to happen to me post-transplant, but I do feel like psychologically there needs to be some improvement emphasizing for patients that their brain might go through some changes.” When delivering care, physicians should be attuned to these challenges for comprehensive patient care. 

      2. Build resilience for the lifelong journey 

      Transplant recipients will undergo changes post-transplant that can be difficult to accept. Dr. Gragossian says, “It’s going to be hard to get 100% back to the person you were before your transplant, and as a patient, one of the things that helped me the most was coming to terms with the fact that there is only so much that I can change.” Patients can benefit from this reminder from their care team to help them understand that “despite not being able to do what they previously could, the new normal is still great.”

      3. Provide clarity and support for lifestyle changes  

      New needs, such as household precautions, changes in diet, and travel considerations may be overlooked by the care team following transplant procedures. Dr. Gragossian notes transplantation requires new medications that compromise the immune system. Transplant recipients must be cautious with certain foods, such as grapefruits and pomegranates, to avoid interactions with certain medications. Additionally, some medications that elevate potassium levels – so patients can only eat traditionally healthy foods such as spinach and bananas in moderation. Support and thorough explanations about newly prescribed medications are crucial to ensure patients know how to use them. Additionally, providing them with solutions for managing their new lifestyle changes is critical. Dr. Gragossian recommends creating an emergency plan for unexpected events.  Dr. Gragossian suggests four travel tips for transplant recipients:  

      • Pack extra medications for at least 3 days.
      • Bring a copy of your medical records.
      • Tell your transplant team that you’re traveling.
      • Be prepared with contact information for the transplant center and local pharmacy at your destination.

      4. Enter each appointment with empathy and understanding 

      Navigating doctor appointments as a transplant recipient can be daunting. Dr. Gragossian says, “I try to remind [my physician colleagues] that when you’re seeing a transplant recipient, you’re probably the 10th doctor that they’ve seen that week and sometimes it could just get a little difficult, and stressful seeing so many health care professionals in such a small amount of time. I also, on the other end, tell transplant recipients sometimes if they go to a doctor who’s not as mindful, it’s only because they’re not used to seeing transplant recipients. There aren’t that many of us. So it’s important for everybody to just take a walk in each other’s shoes and understand that it’s a very complicated space to be in.” In addition to showing empathy and understanding towards patients, physicians need to stay informed about the transplantation world to best serve their patients by showing attention to their condition.

      5. Assist patients in finding peers to relate to 

      As a young transplant recipient, Dr. Gragossian found a connection with other transplant recipients via social media through a supportive community through a Facebook support group for women in their 20s and 30s with heart transplants. Patients may not always know where to seek assistance and community, or even ask about it. However, questions about day-to-day life and emotional burdens that remain unanswered in the medical space can be discussed in support networks. A recommendation from the care team can encourage a transplant recipient to find and trust a community of peers for social and emotional support.

      6. Support the vital role of caregivers

      Dr. Gragossian also advocates for providing extra resources to families and caregivers during the transplantation process to ensure that they are informed and aware of what’s happening every step of the way.  She shared, “We also have to care more about the caregivers. This includes parents and professional caregivers together. I do think that my parents – who were my primary caregivers after my transplant – went through the most trouble. To this day they remember things that I don’t because I was sedated, or I was in a coma. There just weren’t enough resources for parents, caregivers, spouses, and anyone in general who needs help with things like this.” Physicians can contribute to this cause by providing guidance, resources, and encouragement for the patient’s support system.


       

      For more information about the Pediatric and Rare Liver Diseases Council or to learn more about joining, please visit our webpage or email pedsrare@globalliver.org.

      Congress passes Continuing Resolution to extend federal funding into March 2024

      Congress passes Continuing Resolution to extend federal funding into March 2024

      Hpu Header New

      POLICY Logo

      Congress has again averted a government shutdown through the passage of a Continuing Resolution (CR) for funding the government into early March 2024. Election year politics make bipartisanship essential to advancing key legislation in the House and Senate. The current administration will be looking to finalize program regulations and advance key administration priorities before the elections.


      The government averted a shutdown, but work continues to advance FY 2024 appropriations bills to keep the government funded throughout the Fiscal Year.

      The CR keeps certain elements of the U.S. government funded through early March, with federal health programs funded through March 8, 2024. Still, Congress will need to keep passing Continuing Resolutions or pass the Fiscal Year 2024 appropriations bills to continue averting a government shutdown. GLI continues to support funding levels reflected in the Senate appropriations bills, providing modest increases to key healthcare programs and activities and directing funds for a NAFLD/MASLD study. Please help by reaching out to your legislators!


      GLI Celebrates DOJ Action under the ADA That Protects Care to Hepatitis C Patients 

      The US Justice Department (DOJ) and the Department of Health and Human Services (HHS) issued a joint letter to state Medicaid administrators urging, in accordance with the Americans with Disabilities Act, that their Medicaid programs allow people who have both hepatitis C and substance use disorder (SUD) to access life-saving HCV medications called direct-acting antivirals (known as DAAs). GLI has long advocated for the enforcement of policies against discrimination and applauds this action. As we seek to eradicate hepatitis C and prevent liver cancer in the US, no state should be using SUD as a reason to deny access to a life-saving medication for hepatitis C. View the DOJ press release, Harvard Center for Health Law and Policy Innovation press release and comments from GLI and others calling for the HHS Office for Civil Rights to advance a rulemaking that bars this kind of discrimination against people with HCV and SUD.


      Victory for Patients: Copay Assistance Counts as Patient Cost Sharing

      Last year, GLI and 29 advocacy organizations filed an amicus brief in support of a case challenging a rule that would allow health insurers to avoid counting the value of drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations. GLI is excited to report that the U.S. Justice Department has moved to withdraw its appeal of the patient community’s victory last year, which struck down the 2021 HHS rule. The earlier 2020 rule is now in effect, requiring copay assistance to count as patient cost-sharing for prescription drugs, except for brand-name drugs with a generic equivalent. 


      CMS Acknowledges Need to Cover Obesity Treatments 

      GLI strongly supports efforts to convince CMS to cover obesity treatments. GLI applauds that CMS recently recognized scientific advancements in anti-obesity medications. As part of a recent proposal, CMS acknowledged that the Medicare Part D exclusion of drugs for anorexia, weight loss or weight gain is a barrier to coverage outside the Medicare program. GLI provided comments to CMS underscoring the relationship obesity has with other burdensome and costly conditions such as NAFLD/MASLD, and its advanced form, NASH/MASH. The Obesity Care Action Network, of which GLI is a member, also provided extensive comments urging CMS to recognize obesity as a complex and chronic disease and require QHPs to cover all evidence-based treatment services under the appropriate EHB categories. GLI also joined the National Hispanic Council on Aging letter urging Congressional action to cover obesity treatments. You can help by contacting your legislator!


      GLI Supports the Medical Nutrition Equity Act

      GLI is pleased to support the Medical Nutrition Equity Act (H.R. 6892), providing for the coverage of medically necessary food, vitamins, and individual amino acids for digestive and inherited metabolic disorders under Federal health programs and private health insurance, as well as ensuring State and Federal protection for existing coverage. Malabsorption due to liver or pancreatic disease is explicitly included in coverage under the bill’s provisions. 


      GLI Urges Reversal of Policies Obstructing Access to Endoscopies and Colonoscopies

      GLI joined clinicians and 17 leading patient advocacy organizations in calling on UnitedHealthcare (UHC) to reverse its obstructive policies that threaten to disrupt its 27.4 million commercial beneficiaries’ access to virtually all endoscopies and colonoscopies. UHC’s Advance Notification Program lays the foundation for the implementation of UHC’s GI endoscopy “Gold Card” prior authorization program in early 2024. GLI is concerned that the program will require GI practices to spend hours providing UHC with data duplicative of what is already provided in claims forms, slowing access to patient care.


      GLI Urges Improved Access to Colorectal Cancer Screenings

      GLI and 90 medical societies and patient advocacy organizations have banded together to push federal agencies for improved access to life-saving colorectal cancer screenings, calling for the Departments of Health & Human Services, Labor, and Treasury to issue policy clarifications that ensure surveillance colonoscopies are covered as a preventive service under the Affordable Care Act.


       

      [dssb_sharing_buttons icon_placement=”icon” use_custom_icon_size=”on” icon_font_size=”16px” icon_bg=”#98002E” _builder_version=”4.19.4″ _module_preset=”default” background_color=”RGBA(255,255,255,0)” width=”80%” width_tablet=”80%” width_phone=”80%” width_last_edited=”on|tablet” max_width=”100%” module_alignment=”center” custom_margin=”0px||||false|false” custom_padding=”0px||0px||true|false” custom_css_main_element=”margin-top:20px;” border_radii_icon=”on||||” global_colors_info=”{}” alignment_tablet=”left” alignment_phone=”left” alignment_last_edited=”on|tablet” theme_builder_area=”post_content”][dssb_sharing_button _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][/dssb_sharing_button][dssb_sharing_button social_network=”twitter” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][/dssb_sharing_button][dssb_sharing_button social_network=”pinterest” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][/dssb_sharing_button][dssb_sharing_button social_network=”linkedin” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][/dssb_sharing_button][/dssb_sharing_buttons]
      GLI VP Raises NASH Awareness in the Managed Care Community – NASH News

      GLI VP Raises NASH Awareness in the Managed Care Community – NASH News

      Nash News Banner Xl


       

      GLI VP Raises NASH Awareness Among Health Care Community

      Jeff McIntyre, VP of Liver Health Programs at GLI, emphasized the importance of understanding NASH and its global impact during the AMCP Nexus session Navigating NASH: A Discussion on Clinical Background, Patient Advocacy, and Managed Care Considerations.” McIntyre emphasizes how crucial it is to bridge the knowledge gap about NASH within the healthcare community, especially among managed care professionals, given the disparity between liver disease prevalence and public awareness. Early screening and ongoing lifestyle modifications are key and must be built into standard patient care pathways and support.

      Screenshot 2024 02 05 At 10.09.51 AM

       

      Healthcare Professionals Call for Immediate Response to the Severity of Fatty Liver Disease in the Philippines

      As noted in GLI’s Global State of Liver Health report, one out of four people globally is impacted by NAFLD, with approximately 16,500 individuals in the Philippines succumbing to liver disease complications each year. Medical experts from the nation recently highlighted the importance of proactive self-care and holistic well-being to combat NAFLD’s impact, urging individuals to prioritize liver health and take preventive measures against the disease.

      Self Care Medical Consultation

       

      Meet Olivia, Her Liver’s #1 Fan

      Madrigal Pharmaceuticals launched their “Be Your Liver’s #1 Fan” video campaign with the first of a series patient service announcements to raise awareness about liver health. In Meet Olivia, Her Liver’s #1 Fan, the lighthearted yet informative approach underscores the seriousness of fatty liver disease, promotes early detection, and encourages viewers to engage in conversations about liver health.

      Olivia2 Edit

       

      Fatty Liver Disease More Fatal for Women

      A recent study in the Journal of Hepatology found that fatty liver disease (otherwise known as steatotic liver disease), is more fatal for women than for men even though men are more likely to develop it. This finding held true both for alcohol-associated fatty liver disease and when alcohol was not involved. Fatty liver must be detected early and addressed as soon as possible – even among populations who are less likely to develop it – in order to achieve equitable health outcomes.


       

      Global Fatty Liver Day – 5 months to go!! 🥳

      Global Fatty Liver Day - 2024 Save The Date Banner

      Formerly known as International NASH Day

      Fatty liver disease often lurks undetected, impacting millions worldwide and serving as a significant risk factor for concurrent conditions. Left unchecked, it may progress to severe complications, including cirrhosis, liver cancer, and the need for a liver transplant.

      Your involvement matters. The support from our partners is instrumental in the success of our campaign, and we invite you to stand with patients, advocate for early detection, and passionately champion the movement. By becoming an official partner, you’ll join a global network committed to making a positive impact.

      Join us for Global Fatty Liver Day 2024 and visit our Partner Application page.


       

      Rare Advocacy on Capitol Hill, in the White House, & Beyond! – Pediatric & Rare Liver Diseases News

      It’s Rare Liver Diseases Month! – Pediatric & Rare Liver Diseases News

      New Banner 02


       

       

      It’s Rare Liver Diseases Month!

      If you haven’t already, join us for the 2024 #RareAware multifaceted campaign, focusing on the theme of “Transitions in Care”:

      • Hear from patients and caregivers during weekly #GLILIVE conversations on Wednesdays at 12pm ET.
      • Join our Empowerment Day virtual seminar for pediatric patients (ages 8-18), on February 17, 2024, which will connect individuals who have successfully navigated care transitions with those currently undergoing similar journeys. Register here
      • Help us spread awareness about rare liver diseases by sharing graphics on social media using our toolkit
      • Show your support by checking out our merch!

      Learn more about the campaign by reading our press release or checking our website.

        2024 February Is (1)

         

        Congratulations to the Children’s Hospital Los Angeles on their 500th Liver Transplant 

        In January of this year, the Children’s Hospital Los Angeles (CHLA) marked a significant milestone by completing its 500th liver transplant. Since their first liver transplant in 1998, CHLA has progressed to achieve a one-year patient and graft survival rate of 100%.

        CHLA Butterfly Logo® No Tagline

         

        Celebrating VUMC’s First Combined Lung and Liver Transplant

        Vanderbilt University Medical Center (VUMC) reached a significant milestone by conducting its first combined lung and liver transplant on a patient with a rare autoimmune disease known as sarcoidosis. This accomplishment highlights that multidisciplinary care is crucial in the complex, innovative solutions to complex conditions.

        Vanderbilt University Medical Center (VUMC) logo

         

        mRNA Therapies as a Potential Therapy for Argininosuccinic Aciduria

        A recent study using a mouse model has shown the potential effectiveness of messenger RNA (mRNA) therapies for treating the rare liver genetic disease argininosuccinic aciduria (ASA). ASA is an inherited metabolic disorder that affects how the body breaks down protein. ASA can lead to liver dysfunction and damage due to high levels of ammonia accumulating in the liver and bloodstream. Further exploration of this mRNA therapy offers hope for addressing not only ASA but also other rare, incurable genetic diseases.


         

        Exciting Collaboration on the Horizon for Rare Liver Disease Gene Therapy 

        Swiss biotech company Genevant Sciences and gene editing firm Tome Biosciences have joined forces to address an undisclosed monogenic liver disease. Their collaboration seeks to combine Genevant’s lipid nanoparticle technology with Tome’s programmable genomic integration technology, aiming to create an in vivo gene editing treatment. This partnership is an exciting application of novel techniques for rare liver disease patients!

        Genevant logo

         

        Upcoming Events


         

        For more information about the Pediatric and Rare Liver Diseases Council or to learn more about joining, please visit our webpage or email pedsrare@globalliver.org.

        Navigating Liver Cancer Care – Liver Cancers News

        Using Microscopic Bubbles to Blast Cancer & More

        Liver Cancer News Banner


        New Technique Uses Microscopic Bubbles to Blast Cancer  

        This new ultrasound transducer allows doctors to precisely hone in on the tumor and release thousands of sonic energy pulses. The ultrasound pulses then use the body’s natural tissue gasses to create microbubbles that break-up liver cancer tumors. Currently, the Edison Histotripsy System is only being used on patients with certain types of tumors; however, doctors aim to use this non-invasive device for the treatment of gastrointestinal and abdominal cancers in the years to come.

        12bce9de1677341bbeea79f84985

         

        AstraZeneca’s EMERALD-1 Phase III Trial Shows Improved Clinical Outcomes  

        Transarterial chemoembolization (TACE) has been a common treatment option for patients experiencing hepatocellular carcinoma (HCC). This procedure restricts blood supply to the tumor and allows other forms of treatment, such as chemotherapy and radiation therapy, to be administered directly to the liver. Although TACE is common, patients can experience disease progression or recurrence in less than a year. In a phase III clinical trial that attempts to improve these outcomes, AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinical improvement in the progression-free survival compared to TACE alone.


         

        Liver Cancer Rates Increase In Mexican Americans 

        Over the last forty years, liver cancer rates in the United States have tripled, with third-generation Mexican Americans being 66% more susceptible to developing liver cancer compared to their first-generation counterparts. The National Cancer Institute has provided funding to USC’s Keck School of Medicine to investigate the growing disparities among Mexican Americans and their increased risk of liver cancer. Studies have identified risk factors like obesity, diabetes, excessive alcohol consumption, and smoking as contributing to this concerning trend.


         

        TriSalus Developing Novel Therapeutic Solutions for Liver and Pancreatic Tumors

        Chemoembolization, radioembolization, and immunotherapy are critical treatments for the cure of liver cancer, however, a persistent barrier to these treatments has been intratumoral pressure, which limits the delivery of treatment. To combat this obstacle, TriSalus launched the TriNav Infusion System to be used in patients with hepatocellular carcinoma and colorectal cancer. This unique drug delivery technology is intended to open and close with the patient’s cardiac system, allowing increased medication delivery to the targeted tumor.


         

        Dr. Kim on Ongoing and Planned Research in HCC at Moffitt Cancer Center 

        Global Liver Institute’s Liver Cancer Council member, Dr. Richard Kim, explained how Moffitt Cancer Center is at the forefront of using a specific agent that targets the STAT3 pathway. In an ongoing trial, the effectiveness of the STAT3 inhibitor, TTI-101, is being assessed as a standalone treatment for patients who have not responded to previous therapies. This trial will evaluate safety and tolerability of the medication, while future trials will look at these features in combination with pembrolizumab or with atezolizumab and bevacizumab for patients with hepatocellular carcinoma.


         

        Screenshot 2024 02 05 At 9.49.40 AM

         

        Upcoming Events:


         

        For more information about the Liver Cancers Council or to learn more about joining, please visit https://globalliver.org/liver-cancers-council/ or email cancer@globalliver.org

        For Rare Liver Disease Patients, Care Transitions Pose Yet Another Risk

        For Rare Liver Disease Patients, Care Transitions Pose Yet Another Risk

        Event Featured Image Template

         For Rare Liver Disease Patients, Care Transitions Pose Yet Another Risk

        Global Liver Institute Leads Rare Liver Diseases Month Campaign to Highlight Ways to Smooth Care Transitions

        (Washington D.C., February 1, 2024) – Today marks the start of Global Liver Institute’s (GLI) 2024 #RareAware campaign, which calls attention to the more than 100 rare liver diseases throughout February, Rare Liver Diseases Month. Drawing upon insights from patients, caregivers, advocacy groups, clinicians, and other interested parties, the campaign addresses the challenges that transpire when someone with a rare liver disease encounters a transition – whether from pediatric to adult care, from pre- to post-transplant, from inpatient to outpatient care, or another transition.

        Over 100 pediatric and rare liver diseases persist around the world. Rare liver diseases, in many cases, require life-long management, including both inpatient and outpatient care, serious procedures, and lifestyle interventions. For instance:

        “Rare liver disease patients face needless obstacles just to receive an accurate diagnosis and the care they require,” shared Donna R. Cryer, JD, founder and CEO of GLI. “Transitions in care are inevitable – especially when a disease develops during childhood. Yet without intentional preparation, discussion, and guidance, a predictable transition can become a complicated, confusing, and even fatal process. Everyone involved – from caregivers and patients to clinicians and social workers – should begin open, thorough discussion as soon as a transition is on the horizon.”

        Transitions in care can not only be confusing but also financially costly. Each year, acute care for Medicare patients (which includes those under 65 with end-stage renal disease or who receive disability benefits) costs $26 billion. Unexpected financial burdens can lead to medical bankruptcy or create barriers and delays to home ownership, higher 

        education, and other foundational financial investments. To avoid negative impact on health, wealth, and overall well-being, patients and everyone on their new care team must have informed discussions about both what is going on and what they are responsible for.

        GLI is leading those discussions throughout the campaign with useful educational materials, an Empowerment Day for pediatric patients, informative conversations about different aspects of care transitions, and Q&As with experts. The campaign culminates in advocacy efforts to increase policy attention to rare liver diseases on the rarest day on the calendar, February 29 – Rare Disease Day.

        No matter the role, each person can make a difference to ensure smooth transitions in care for patients with rare liver disease.

        • Patients: Use your rare voice to ask your care team about upcoming changes, to advocate for the resources and information you need, and to share your story with your community.
        • Caregivers and family: Consider asking your loved ones how they are preparing physically and emotionally for upcoming changes, how you can help, and how it might change the dynamics of your relationship with them.
        • Clinicians: Ensure that you are listening thoughtfully to your patients, preparing them for the changes ahead, and maintaining an unencumbered line of communication with their new providers.
        • Healthcare administrators: Create, fund, recruit, and train a robust staff of nurse navigators and social workers so that a knowledgeable guide can walk alongside patients through transitions in care within your system.
        • Industry leaders: Involve patient input and patient priorities in the drug development and implementation processes to ensure the tools exist to meet patient priorities and needs across the continuum of care.

        Learn more about the month-long #RareAware campaign and GLI’s year-round activities to support pediatric and rare liver disease patients at globalliver.org.

        About Global Liver Institute 

        Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. GLI holds Platinum Transparency with Candid/GuideStar, is a member of the National Health Council, and serves as a Healthy People 2030 Champion. Follow GLI on Facebook, Instagram, LinkedIn, and YouTube or visit www.globalliver.org.